<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Obsessive-compulsive disorder in children and adolescents: Treatment overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Obsessive-compulsive disorder in children and adolescents: Treatment overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Obsessive-compulsive disorder in children and adolescents: Treatment overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Rosenberg, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Brent, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 28, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H19048522">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Obsessive-compulsive disorder (OCD) is characterized by recurrent intrusive thoughts, images, or urges that cause anxiety or distress (obsessions), and by repetitive mental or behavioral acts (compulsions) that the individual feels driven to perform. Compulsions are done in response to the obsession (ie, to decrease distress or prevent a feared consequence from occurring). Almost all individuals with OCD have both obsessions and compulsions. Individuals with OCD typically have insight that obsessions and compulsions are excessive and unreasonable although clearly expressed insight can be absent especially in younger children with OCD.
        </p>
        <p>
         OCD typically starts in childhood or adolescence. If not successfully treated, it often persists throughout life and produces substantial impairment in functioning. Few patients with OCD get substantially better without evidence-based treatment.
        </p>
        <p>
         Treatments with the most empirical support for OCD in children and adolescents include serotonergic antidepressants (eg, selective serotonin reuptake inhibitors [SSRIs] or
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         ), cognitive-behavioral therapy with exposure and response prevention (CBT-ERP), or a combination of the two. (See
         <a class="local">
          'Initial treatment'
         </a>
         below.)
        </p>
        <p>
         This topic and an associated algorithm review our preferred choices for treatment of OCD in children and adolescents  (
         <a class="graphic graphic_algorithm graphicRef143692" href="/z/d/graphic/143692.html" rel="external">
          algorithm 1
         </a>
         ). The epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis of OCD in children and adolescents and discussion of pediatric acute-onset neuropsychiatric syndrome (PANS) and pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS) are discussed separately. Topics related to OCD in adults are also found separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/86436.html" rel="external">
          "Obsessive-compulsive disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14629.html" rel="external">
          "Management of obsessive-compulsive disorder in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/498.html" rel="external">
          "Obsessive-compulsive disorder in adults: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14636.html" rel="external">
          "Obsessive-compulsive disorder in adults: Psychotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6031.html" rel="external">
          "PANDAS: Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1000386293">
         <span class="h1">
          INITIAL TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our preference for initial treatment modality is based on severity of symptoms, presence of active comorbid disorder, and past treatment history. We prioritize patient/caregiver preference and typically initiate treatment with the patient preferred option. For example, if an individual expresses an interest in combined treatment, we would begin with this, if available. If the individual refuses to begin psychotherapy (despite our recommendation) or if psychotherapy has been ineffective, we would treat with pharmacologic management as monotherapy. (See
         <a class="local">
          'Mild or moderate symptoms'
         </a>
         below and
         <a class="local">
          'Severe symptoms or active comorbid disorder'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H207078085">
         <span class="h2">
          Mild or moderate symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         For youth with obsessive-compulsive disorder (OCD), whose symptoms are mild or moderate (eg, Children’s Yale-Brown Obsessive Compulsive Scale [CY-BOCS] &lt;24), who do not have an active co-occurring disorder, and who are willing to participate in psychotherapy, cognitive-behavioral therapy with exposure and response prevention (CBT-ERP) is our preferred choice (see
         <a class="local">
          'Administration of CBT-ERP'
         </a>
         below and
         <a class="local">
          'Efficacy of CBT-ERP'
         </a>
         below). No other psychotherapies for OCD in youth have received comparable study nor have they demonstrated consistent efficacy in clinical trials.
        </p>
        <p class="headingAnchor" id="H4045916624">
         <span class="h3">
          Administration of CBT-ERP
         </span>
         <span class="headingEndMark">
          —
         </span>
         CBT-ERP may be administered in person or via internet.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          In-person cognitive-behavioral therapy (CBT)
         </strong>
         – The basic approach and components of effective CBT programs for children with OCD are similar [
         <a href="#rid1">
          1
         </a>
         ]. The program consists of 14 hour-long sessions over a 12-week period in sessions with the child and one or more family members [
         <a href="#rid2">
          2
         </a>
         ]. These are supplemented by 10-minute phone sessions most weeks. The therapy is typically provided individually, but evidence supports its use in groups and with/without participating family members [
         <a href="#rid3">
          3,4
         </a>
         ]. The framework and administration described here are from a widely used and well-studied program [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="local">
          'Components'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Internet-delivered
         </strong>
         – Internet-delivered CBT may be as effective as face-to-face CBT for pediatric OCD. In most countries, children and adolescents with OCD have limited access to CBT provided by a specialist; internet-delivered treatment may help CBT to reach more individuals by breaking down the barriers to accessibility [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In one trial, 152 youth with OCD were assigned to receive 16 weeks of internet-delivered stepped-care CBT versus face-to-face CBT [
         <a href="#rid5">
          5
         </a>
         ]. At six-month follow-up, improvements in children and adolescents using internet-delivered CBT were not statistically different from those using face-to-face CBT (mean difference 0.91 points on the 40-point CY-BOCS).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2639217638">
         <span class="h3">
          Components
         </span>
         <span class="headingEndMark">
          —
         </span>
         We involve parents/caregivers in all aspects of treatment with CBT when it is used to treat pediatric OCD. In treating children with CBT, we customize the treatment to the developmental limitation of the child. CBT has been used with good results in children as young as five years.
        </p>
        <p>
         The program is delivered in five phases of treatment [
         <a href="#rid2">
          2
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychoeducation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cognitive training – A nonpharmacologic approach that involves use of mental activities designed to maintain or increase cognitive processes (see
         <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">
          "Attention deficit hyperactivity disorder in adults: Psychotherapy", section on 'CBT targeting executive dysfunction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/82780.html" rel="external">
          "Attention deficit hyperactivity disorder in adults: Psychotherapy", section on 'Format and availability'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mapping OCD and case formulation [
         <a href="#rid6">
          6
         </a>
         ] – “Mapping OCD” is a process of identifying and describing hypothesized causes/origins of symptoms, and addressing triggers of symptoms and problematic behaviors
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Graded exposure and response prevention (see
         <a class="medical medical_review" href="/z/d/html/15927.html" rel="external">
          "Psychotherapy for anxiety disorders in children and adolescents", section on 'Conceptualization and components'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Relapse prevention and generalization training
        </p>
        <p>
        </p>
        <p>
         Further discussion of psychotherapy for anxiety disorders in children, administration, and components of CBT in treatment of adults with OCD, and overview of psychotherapies is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14612.html" rel="external">
          "Overview of psychotherapies"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14636.html" rel="external">
          "Obsessive-compulsive disorder in adults: Psychotherapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15927.html" rel="external">
          "Psychotherapy for anxiety disorders in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H773597299">
         <span class="h3">
          Efficacy of CBT-ERP
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials indicate that treatment with CBT-ERP, as compared with control, waitlist, or placebo condition, leads to a greater reduction in symptom severity [
         <a href="#rid7">
          7-11
         </a>
         ]. For example, in a meta-analysis including nine trials and 645 youth with OCD, treatment with CBT-ERP was compared with control condition [
         <a href="#rid9">
          9
         </a>
         ]. Subjects in the CBT group had a greater reduction OCD symptom severity as compared with the control group (mean difference 6.81 points on the CY-BOCS, 95% CI 8.45-5.18). However, the findings are of low certainty due to heterogeneity of methods and risk of bias.
        </p>
        <p class="headingAnchor" id="H3826846859">
         <span class="h2">
          Severe symptoms or active comorbid disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals with severe symptoms (eg, CY-BOCS score ≥24) and in those with active comorbid disorders (eg, depression, anxiety disorder) we prefer treatment with combined modality including pharmacotherapy and CBT-ERP. However, in some cases the severity of the comorbid disorders may preclude participation in CBT-ERP, or CBT-ERP may be unavailable. In these cases, we typically begin with pharmacologic management until the individual can effectively work in CBT to address the symptoms of OCD.
        </p>
        <p class="headingAnchor" id="H2961823774">
         <span class="h3">
          SSRI as first pharmacologic choice
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals who will be starting on pharmacotherapy alone (eg, prior unresponsiveness to psychotherapy, refusal to engage in psychotherapy, lack of access to timely CBT) or as part of combination treatment (ie, severe symptoms, co-occurring disorder, patient preference), our preference is treatment with a selective serotonin reuptake inhibitor (SSRI) rather than other antidepressants (eg,
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         , serotonin-norepinephrine reuptake inhibitors). Our preference for SSRIs is based on their efficacy combined with their superior side effect profile (as compared with clomipramine), and their ease of use. (See
         <a class="local">
          'Choosing among SSRIs'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2008858256">
         <span class="h3">
          Choosing among SSRIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         We choose from among SSRI medications based on the side effect profile, drug-drug interactions, prior treatment response, comorbid psychiatric conditions, and family history. In cases where the individual has successfully responded to an agent in the past, we often choose that agent again. Additionally, if there is a family history of response to specific medication, we would typically choose this as the first pharmacologic choice.
        </p>
        <p>
         Several SSRI medications including
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13025" href="/z/d/drug information/13025.html" rel="external">
          fluvoxamine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="12681" href="/z/d/drug information/12681.html" rel="external">
          paroxetine
         </a>
         , and the non-SSRI,
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         have shown favorable comparison to placebo in the treatment of pediatric OCD (see
         <a class="local">
          'Efficacy of SSRIs'
         </a>
         below) [
         <a href="#rid12">
          12-27
         </a>
         ]. However, few comparative treatment studies have been performed and there is minimal guidance on preferred choice of SSRIs in the treatment of pediatric OCD. Medications used in the treatment of pediatric OCD are shown on the associated table  (
         <a class="graphic graphic_table graphicRef95416" href="/z/d/graphic/95416.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H2495757166">
         <span class="h3">
          Starting and titrating SSRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         We start at a low initial starting dose and increase slowly and in small increments in all youth being treated with SSRIs for pediatric OCD. We do this to avoid side effects and increase tolerability. As an example, when using
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         , we typically begin at 12.5 (for a child) to 25 mg per day (for an adolescent) and monitor for one week. We then titrate, as tolerated, by 25 mg (for a child) to 50 mg (for an adolescent) no faster than every two weeks (depending on patient response and tolerance) to a dose at the lower end of the maintenance daily dose range (eg, 25 to 75 mg)  (
         <a class="graphic graphic_table graphicRef95416" href="/z/d/graphic/95416.html" rel="external">
          table 1
         </a>
         ). The speed of titration can be adjusted based on the overall severity and impairment related to OCD, the presence and severity of comorbid anxiety and depressive symptoms, and tolerability of the medication.
        </p>
        <p class="headingAnchor" id="H3942933536">
         <span class="h3">
          Dose and length of trial
         </span>
         <span class="headingEndMark">
          —
         </span>
         We monitor for 12 weeks at the lower end of the maintenance daily dose range (eg, 25 to 75 mg). If adequate response is not achieved, we make subsequent gradual increases in weekly increments to maximize efficacy and minimize toxicity. We increase the dose until clinical response is seen or the maximum tolerated dose within the maintenance dose range is reached. We monitor at this dose for 6 to 12 weeks. For example, in the above trial using
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         in the treatment of an adolescent with OCD, after 12 weeks at the lower end of maintenance dose range (eg, 25 to 50 mg) we would increase by 25 mg per day increments once weekly until clinical response is achieved or the maximum dose of 200 mg is reached.
        </p>
        <p>
         We consider a full therapeutic trial to be at least 12 weeks with at least 6 at the maximum tolerated dose within the daily dose range. Improvement of OCD symptoms may occur slowly (eg, several months), particularly with
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         . We explain this to the patient and their family so that they do not prematurely stop the medication before a full therapeutic trial has been completed.
        </p>
        <p>
         Common side effects of SSRIs include sexual dysfunction, gastrointestinal effects (diarrhea or nausea), headache, fatigue, or insomnia. Pediatric patients are reported to have an increased risk of side effects associated with SSRIs including treatment emergent suicidal ideation, behavioral activation, and mania [
         <a href="#rid28">
          28,29
         </a>
         ]. Titrating the dose upward toward maximum tolerated ranges in children who do not or only partially respond to minimum-dose SSRI therapy is acceptable, particularly given the more benign side effect profile of SSRIs compared with other pharmacologic options in pediatric OCD.
        </p>
        <p>
         However, the safety profile of supratherapeutic-dose SSRI treatment has not been sufficiently studied and, contrary to adult OCD, we do not recommend exceeding the US Food and Drug Administration (FDA)-recommended dose ranges in children and adolescents with OCD [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
         Our clinical experience and available research suggests that pediatric patients with OCD who demonstrate a clinical response, but not full or partial remission, to 12 weeks of SSRI treatment (with at least six weeks at maximum tolerated dose) continue to experience further improvement (average approximately 30 percent) beyond the 12-week duration of clinical trials [
         <a href="#rid31">
          31,32
         </a>
         ]. An uncontrolled trial tested the continuation of
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         (50 to 200 mg/day) for 52 weeks in 72 6- to 12-year-olds and 65 13- to 18-year-olds with OCD who already completed a 12-week clinical trial of sertraline [
         <a href="#rid31">
          31
         </a>
         ]. At the end of the study period, 55 percent of patients met criteria for full remission (CY-BOCS ≤8) and 31 percent met criteria for partial remission (CY-BOCS ≤15).
        </p>
        <p class="headingAnchor" id="H111954337">
         <span class="h3">
          Monitoring and defining response
         </span>
         <span class="headingEndMark">
          —
         </span>
         In outpatient practice, we typically monitor individuals who have started on antidepressants weekly for the first month, twice monthly for one month, and then at least monthly thereafter [
         <a href="#rid33">
          33
         </a>
         ]. The frequency of the visits depends on the severity of symptoms, whether suicidal ideation or mania is emergent, the complexity of comorbid disorders and the presence of side effects. Individuals with any of these are seen more frequently.
        </p>
        <p>
         At each visit, we evaluate for symptomatic improvement using the CY-BOCS, a self-report or family report scale. Response is defined as a reduction in CY-BOCS score of 35 percent. Partial treatment response is defined as a reduction in CY-BOCS score between 25 to 35 percent. Remission is defined as a total score of ≤12. (See
         <a class="medical medical_review" href="/z/d/html/86436.html" rel="external">
          "Obsessive-compulsive disorder in children and adolescents: Epidemiology, pathogenesis, clinical manifestations, course, assessment, and diagnosis", section on 'Rating scales'
         </a>
         .)
        </p>
        <p>
         Additionally, we review for the presence of mania or suicidal thoughts and for the presence of medication side effects (see
         <a class="local">
          'Side effects'
         </a>
         below). We get caregiver perspective on the patient progress and reiterate to the patient and family the need for a full therapeutic trial. (See
         <a class="local">
          'Dose and length of trial'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2567137397">
         <span class="h3">
          Side effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         We review side effects and adverse effects of medication at each visit. Additionally, as treatment emergent suicidal ideation or medication-induced mania are a consideration in youth treated with SSRI medication, therefore we assess for these symptoms at each visit.
        </p>
        <p>
         Side effects of SSRI medications are typically dose dependent and often dissipate over time [
         <a href="#rid34">
          34-37
         </a>
         ]. The most common side effects include headache, abdominal pain, nausea, diarrhea, sleep changes, weight gain, and jitteriness or agitation.
        </p>
        <p class="headingAnchor" id="H2686467970">
         <span class="h4">
          Suicidality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Despite controversy about the relationship between SSRI use and suicidality in children, we monitor for suicidality at each visit. All antidepressants used in the United States have a boxed warning by the FDA about suicidality. There appears to be a slightly increased risk of suicidal thoughts and behaviors (but not completed suicide) among a small group of children and adolescents who are treated with antidepressant medications compared with placebo; however, the evidence is inadequate to conclusively establish this association, which is described in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/1225.html" rel="external">
          "Effect of antidepressants on suicide risk in children and adolescents"
         </a>
         .)
        </p>
        <p>
         In a meta-analysis that included six clinical trials of antidepressants for pediatric OCD, the baseline risk of suicidal ideation/suicide attempts in youth with OCD was low, and not statistically different than the rate found in those treated with placebo (0.5 percent, 95% CI -1.2 to 2.2) [
         <a href="#rid28">
          28,37
         </a>
         ]. Review of evidence on the association between SSRIs and suicidality has not found any one SSRI to have a stronger or weaker relationship to suicide than the others. (See
         <a class="medical medical_review" href="/z/d/html/1225.html" rel="external">
          "Effect of antidepressants on suicide risk in children and adolescents"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2674128524">
         <span class="h4">
          Antidepressant-induced mania
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the risk of induction of mania in pediatric patients with depression or anxiety is relatively rare (&lt;2 percent), we are careful to monitor for antidepressant-induced mania in children and adolescents being treated with antidepressants, particularly in those with a history of bipolar disorder.
        </p>
        <p>
         The role of antidepressants in inducing a patient’s switch in mood to mania is controversial. In a sample of 4786 patients age 5 to 29, younger children (age 10 to 14) had a higher risk of mania when treated with antidepressants compared with adolescents and young adults [
         <a href="#rid29">
          29
         </a>
         ]. However, increases in behavioral disinhibition or “behavioral activation” (eg, impulsivity, silliness, irritability, inability to control activity level, attention, and emotions) occur in approximately three to eight percent of youth taking antidepressants [
         <a href="#rid38">
          38
         </a>
         ]. Many patients may also be especially inhibited prior to treatment initiation [
         <a href="#rid39">
          39
         </a>
         ], and differentiation between healthy childhood behavior, “disinhibition,” and mania is important. (See
         <a class="medical medical_review" href="/z/d/html/14655.html" rel="external">
          "Bipolar major depression in adults: Efficacy and adverse effects of antidepressants", section on 'Risk of switching to mania'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2499151142">
         <span class="h3">
          Efficacy of SSRIs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinical trials support the efficacy of serotonergic medications as compared with placebo, in the treatment of pediatric OCD [
         <a href="#rid7">
          7,12-18,40-42
         </a>
         ]. However, there are few trials directly comparing efficacy of SSRIs in its treatment.
        </p>
        <p>
         In a meta-analysis including 12 trials and 1044 youth with OCD the effects of serotonergic medications (SSRIs and
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         ) as compared with placebo was investigated [
         <a href="#rid14">
          14
         </a>
         ]. The overall effect size for medication versus placebo was 0.46 (standardized mean difference, 95% CI 0.37-0.55), equivalent to approximately four points on the CY-BOCS.
        </p>
        <p>
         In clinical trials,
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         [
         <a href="#rid7">
          7,12
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         [
         <a href="#rid15">
          15,16
         </a>
         ],
         <a class="drug drug_pediatric" data-topicid="13025" href="/z/d/drug information/13025.html" rel="external">
          fluvoxamine
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ], and
         <a class="drug drug_pediatric" data-topicid="12681" href="/z/d/drug information/12681.html" rel="external">
          paroxetine
         </a>
         [
         <a href="#rid13">
          13
         </a>
         ] each provided greater improvement in symptoms of pediatric OCD than placebo. As an example, in a trial, 187 youth with OCD were randomly assigned to 12 weeks treatment with sertraline (up to 200 mg/day) or placebo [
         <a href="#rid12">
          12
         </a>
         ]. Subjects treated with sertraline, as compared with those treated with placebo, had a higher rate of response (42 versus 26 percent) and greater improvement on measures of OCD symptoms (CY-BOCS adjusted mean difference -6.8 versus -3.4). Of note, a greater percentage of subjects treated with sertraline, as compared with placebo, terminated treatment early (12 versus 3 percent).
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Comparing and combining modality
         </strong>
         – Treatment with CBT or pharmacologic management with an SSRI appear to have similar efficacy to each other, each with superior efficacy as compared with wait list or control [
         <a href="#rid7">
          7-9
         </a>
         ]. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a multisite trial 112 youth with a diagnosis of OCD and a CY-BOCS score indicating moderate severity OCD (ie, score of ≥16) were randomly assigned to 12 weeks of treatment with CBT alone,
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         alone, combined CBT plus sertraline, or pill placebo alone [
         <a href="#rid7">
          7
         </a>
         ]. Sertraline was dosed using a flexible strategy with an average dose of 170 mg/day (range 25 mg to 200 mg/day). Both sertraline alone and CBT alone reduced OCD symptoms to a similar degree and each greater than placebo. The rate of clinical remission (as defined by CY-BOCS ≤10) was similar between the CBT group (39 percent; 95% CI 24-58) and medication group (21 percent; 95% CI 10-40). Each was greater than the remission rate in the placebo/control group (4 percent; 95% CI 0-19 percent). There were significant site differences in outcomes, suggesting that patient adherence and quality of CBT may have an important effect on efficacy.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In a meta-analysis of treatments for pediatric OCD including 3 trials and 146 subjects, treatment with either CBT or SSRIs led to similar decreases in OCD severity (mean difference -0.75, 95% CI -3.8 to 2.3) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Combined treatment with CBT and a serotonin reuptake inhibitor appears to be more effective than either treatment alone [
         <a href="#rid7">
          7,43
         </a>
         ]. For example, in the trial above [
         <a href="#rid7">
          7
         </a>
         ], a greater proportion of youth treated with combined treatment experienced remission of symptoms as compared with patients receiving
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         alone or placebo alone (56 versus 21 versus 4 percent). Additionally, there was a trend towards greater rate of remission with combined treatment than with CBT alone (56 versus 39 percent). Similar findings have been reported in other studies [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, despite the potential superiority of combined treatment over monotherapy with either treatment, our preference is to provide individuals with treatment that is both effective and with the least potential for side effects. While SSRIs have a relatively benign side effect profile, younger patients may be particularly prone to side effects. In contrast, CBT has no physical side effects while offering comparable symptomatic improvement to treatment with serotonergic medications. However, practical limitations (eg, greater cost, higher frequency of appointments, availability of trained CBT-ERP therapists) may limit the availability of and willingness to participate in psychotherapy. (See
         <a class="local">
          'Mild or moderate symptoms'
         </a>
         above and
         <a class="local">
          'Severe symptoms or active comorbid disorder'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3689703342">
         <span class="h1">
          RESPONSE TO INITIAL TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1735350578">
         <span class="h2">
          Adequate response
         </span>
        </p>
        <p class="headingAnchor" id="H585269793">
         <span class="h3">
          Response to CBT-ERP
         </span>
         <span class="headingEndMark">
          —
         </span>
         As the clinical effects of cognitive-behavioral therapy with exposure-response prevention (CBT-ERP) can decline over time [
         <a href="#rid44">
          44
         </a>
         ], we often offer booster sessions at progressively longer intervals (eg, 1, 3, 6, and 12 months) for the first year after successful treatment. It is estimated that approximately 20 percent of individuals with adequate response to cognitive-behavioral therapy (CBT) may experience recurrent symptoms that require further treatment. The 12 months after CBT completion appear to be a critical period and patients are less likely to experience a relapse in obsessive-compulsive disorder (OCD) if they maintain therapeutic gains throughout this period [
         <a href="#rid45">
          45
         </a>
         ]. Booster sessions oriented toward reminding the child of previously learned exposure-response prevention techniques, supplementing patient knowledge, and checking-in with patients and their family members on treatment progress, may prevent or reverse clinical decline.
        </p>
        <p class="headingAnchor" id="H1783608471">
         <span class="h3">
          Response to SSRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         We continue medications for at least one year in individuals who have adequately responded to initial selective serotonin reuptake inhibitor (SSRI) treatment. However, our treatment plan is individualized to address other factors such as difficulty in reaching stabilization, level of psychosocial impairment, history of prior exacerbation after medication discontinuation, symptom severity, or the presence of clinically active comorbidity. For example, in a youth with OCD who has had recurrence of symptoms in the past upon medication tapering we would likely continue the medication for a longer period of time (eg, two or more years). For an individual with severe symptoms that caused significant psychosocial disruption and in whom stabilization was difficult (eg, several medication trials) we would likely continue treatment for longer than one year.
        </p>
        <p>
         If the decision is made to taper medications, we attempt a gradual taper. Typically, we taper medications by up to 25 percent each month; however, as the dose gets lower, we taper more slowly (eg, 25 percent every two months).
        </p>
        <p>
         When tapering medication, we monitor the child closely and educate the patient and their caregivers about warning signs that symptoms of OCD may emerge. For individuals who have responded to CBT previously, booster CBT sessions may be helpful to prevent symptom relapse during medication tapering.
        </p>
        <p class="headingAnchor" id="H1016968096">
         <span class="h2">
          Inadequate response
         </span>
         <span class="headingEndMark">
          —
         </span>
         For individuals with a partial or inadequate response to initial treatment to any modality (monotherapy, combined therapy), we take the following steps prior to making treatment changes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirm adherence to medication treatment. Ask about adverse side effects that may be limiting adherence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Assess for factors limiting effect of CBT-ERP (ie, motivation for treatment, frequency of sessions, capacity for introspection, adequate exposure rituals being practiced).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Review history of illness to reconfirm the diagnosis and assess for the presence of an undiagnosed comorbid disorder.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H200217982">
         <span class="h1">
          SUBSEQUENT TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         After addressing the factors that might be affecting response to initial treatment (see
         <a class="local">
          'Inadequate response'
         </a>
         above), our subsequent management of obsessive-compulsive disorder (OCD) in youth is as follows  (
         <a class="graphic graphic_algorithm graphicRef143692" href="/z/d/graphic/143692.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="headingAnchor" id="H1900542931">
         <span class="h2">
          Longer term cognitive-behavioral therapy with exposure-response prevention
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with pediatric OCD who initially have a partial response, or fail to respond to cognitive-behavioral therapy (CBT) treatment, our preference is additional CBT treatment to reduce symptoms [
         <a href="#rid46">
          46
         </a>
         ].
        </p>
        <p>
         Our preference is based on the findings of a clinical trial in which 54 youth (age 7 to 17 years) who failed to respond (posttreatment Children’s Yale-Brown Obsessive Compulsive Scale [CY-BOCS] ≥16) to an initial course of CBT (14 sessions of weekly individual exposure-based CBT) were randomly assigned to receive either 10 additional CBT treatment sessions, or treatment with
         <a class="drug drug_pediatric" data-topicid="12787" href="/z/d/drug information/12787.html" rel="external">
          sertraline
         </a>
         , over 16 weeks [
         <a href="#rid41">
          41
         </a>
         ]. No significant differences were seen in outcomes between treatment groups. However, nearly half of patients in each treatment group (50 percent for CBT, 45.4 percent for sertraline) experienced reduced OCD symptoms.
        </p>
        <p>
         However, patient preference is strongly considered in all treatment options. For example, in a patient that is unwilling to engage in further psychotherapy, despite our recommendation as the next step, we would agree to continue treating with medication only.
        </p>
        <p class="headingAnchor" id="H934863661">
         <span class="h2">
          Pharmacologic management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subsequent pharmacologic management of youth with inadequate response to management to this point is discussed below. Our preference is to try the following sequentially.
        </p>
        <p class="headingAnchor" id="H1136076946">
         <span class="h3">
          SSRI trials
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our preference is to try two selective serotonin reuptake inhibitor (SSRI) trials, if response is not achieved, prior to other medication trials (eg,
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         , antipsychotic) in youth with refractory OCD  (
         <a class="graphic graphic_algorithm graphicRef143692" href="/z/d/graphic/143692.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those individuals who have not had a medication trial to this point, we add an SSRI to the current psychotherapy (see
         <a class="local">
          'Choosing among SSRIs'
         </a>
         above and
         <a class="local">
          'Starting and titrating SSRI'
         </a>
         above and
         <a class="local">
          'Dose and length of trial'
         </a>
         above). If this is ineffective, we discontinue the medication and try a second SSRI.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For those individuals who are already on an SSRI treatment our preference is to stop the first medication and immediately start a second medication at an equivalent dose. Overlap in mechanisms of action between SSRIs typically prevents discontinuation symptoms that might otherwise occur when an SSRI is suddenly stopped. However, some clinicians prefer cross-titration (ie, lowering the ineffective medication while simultaneously introducing the new medication)  (
         <a class="graphic graphic_table graphicRef95416" href="/z/d/graphic/95416.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H42416807">
         <span class="h3">
          Change to clomipramine
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          Clomipramine
         </a>
         , a tricyclic antidepressant (TCA) that inhibits reuptake of serotonin and norepinephrine, is the only TCA with demonstrated effectiveness in pediatric OCD [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prior to starting
         </strong>
         <strong>
          clomipramine
         </strong>
         – We review the youths past medical history with attention to prior heart disease including conduction system disease (eg, congenital QT syndrome). We obtain clearance from a cardiologist or primary care provider prior to beginning medication if there is a history of cardiac illness, blood pressure or pulse abnormalities, or adverse electrocardiogram (ECG) findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dose titration and monitoring
         </strong>
         – We typically begin
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         for pediatric OCD starting at 25 mg/day  (
         <a class="graphic graphic_table graphicRef95416" href="/z/d/graphic/95416.html" rel="external">
          table 1
         </a>
         ). We monitor for tolerability for one to two weeks following each dose adjustment. If the medication is tolerated, we increase the dose by 25 mg each week to a total dose of 100 mg/day is reached. At this dose, we monitor for four to six weeks. If therapeutic effect is not seen we increase further in 25 mg intervals until therapeutic effect is seen, side effects limit further increases, or maximum dose of 200 mg per day is reached. Problematic side effects often limit dose escalation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          Clomipramine
         </a>
         levels do not correlate with clomipramine dose. However, we occasionally use clomipramine levels to assess for compliance and toxicity.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Anticholinergic side effects of
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         include sedation, dry mouth, constipation, urinary delay, and orthostatic hypotension [
         <a href="#rid47">
          47
         </a>
         ]. Clomipramine can delay cardiac conduction and like other TCAs may be associated with the rare occurrence of sudden cardiac death in youth. When prescribing clomipramine, we recommend that the patient avoid grapefruit and grapefruit juice, as these can raise the mean plasma concentration of clomipramine [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1717.html" rel="external">
          "Tricyclic and tetracyclic drugs: Pharmacology, administration, and side effects", section on 'Clomipramine'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         –
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          Clomipramine
         </a>
         has been established as an effective treatment for pediatric OCD for over three decades [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In a meta-analysis including five trials and 182 youth with OCD,
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         was found to be superior to placebo or
         <a class="drug drug_pediatric" data-topicid="13210" href="/z/d/drug information/13210.html" rel="external">
          desipramine
         </a>
         (a TCA) in the treatment of pediatric OCD [
         <a href="#rid14">
          14
         </a>
         ]. For example, in one trial, 60 youth with OCD were randomly assigned to receive eight weeks of treatment with clomipramine or placebo [
         <a href="#rid19">
          19
         </a>
         ]. At treatment end, subjects in the active treatment group had a greater reduction in OCD symptoms as compared with placebo (37 versus 8 percent). However, a greater percentage of patients in the treatment group (35 to 68 percent) as compared with the placebo group (9 to 16 percent) experienced dry mouth, somnolence, dizziness, or fatigue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although available research in children suggests that
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         may be more efficacious than SSRIs in pediatric OCD, SSRIs are the preferred treatment because they are better tolerated and safer than clomipramine [
         <a href="#rid14">
          14,49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Head-to-head trials comparing
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         with SSRI have not shown either to be superior for treatment of youth with OCD [
         <a href="#rid20">
          20-26
         </a>
         ]. However, a meta-analysis of trials that did not directly compare SSRIs with clomipramine suggested that clomipramine has a greater effect size than SSRIs in adult OCD [
         <a href="#rid49">
          49
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4100589380">
         <span class="h3">
          Augment with a second-generation antipsychotic
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically use second-generation antipsychotics agents to augment SSRIs in pediatric patients with OCD who have responded insufficiently to treatment to this point.
        </p>
        <p>
         We typically use lower doses of antipsychotics when augmenting serotonin reuptake inhibitor (SRI) medications as compared with those used for treatment of psychotic disorders. For example, we start
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         at 0.25 mg/day and increased weekly in 0.25 mg increments to a maximum of 1.5 to 2 mg/day. A one-month trial is often sufficient to determine effectiveness. In some cases, a longer time period may be necessary particularly if higher doses (eg, 1 to 2 mg/day are needed). Youth treated with atypical antipsychotics are vulnerable to serious metabolic side effects. Children, especially preadolescents, are more sensitive to side effects than other patients, particularly to weight gain, diabetes, carbohydrate abnormalities [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         A table provides a recommended schedule for monitoring metabolic effects of first and second-generation antipsychotics  (
         <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">
          table 2
         </a>
         ). We assess more frequently in patients at higher risk (eg, baseline elevated lipids, glucose, weight) or for patients on specific antipsychotics (eg,
         <a class="drug drug_pediatric" data-topicid="16033" href="/z/d/drug information/16033.html" rel="external">
          olanzapine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="89427" href="/z/d/drug information/89427.html" rel="external">
          quetiapine
         </a>
         , and
         <a class="drug drug_pediatric" data-topicid="12995" href="/z/d/drug information/12995.html" rel="external">
          clozapine
         </a>
         ) where there is clear evidence of an increased risk of insulin resistance [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
         First-generation antipsychotic agents are typically not considered as first-line augmenting agents in youth with OCD because of their side effect profile and limited study in this population.
        </p>
        <p>
         There is strong evidence of the efficacy of antipsychotic augmentation in adults with OCD, although randomized controlled trial data in children are absent. Augmentation with second generation antipsychotic medications is supported by naturalistic open trials of youth with OCD who did not respond sufficiently to monotherapy. Both
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         and
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         were associated with symptom improvement during a comparative study of 69 children with tic-related OCD that did not respond to SSRI monotherapy [
         <a href="#rid52">
          52
         </a>
         ]. Two open trials of 43 and 39 treatment refractory youth found that aripiprazole augmentation of an SRI was associated with symptom improvement in 58 and 59 percent of these patients [
         <a href="#rid53">
          53,54
         </a>
         ]. Risperidone augmentation of an SRI was also associated with OCD symptom improvement in a case series including four youth with OCD who had not responded sufficiently to monotherapy [
         <a href="#rid55">
          55
         </a>
         ].
        </p>
        <p>
         However,
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         was associated with serious metabolic adverse events, such as weight gain, and sedation, while
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         was associated with mild to moderate agitation.
        </p>
        <p class="headingAnchor" id="H443195906">
         <span class="h3">
          Clomipramine plus SSRI
         </span>
         <span class="headingEndMark">
          —
         </span>
         In individuals who have inadequate response to treatment to this point, our next trial is a combination of
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         plus an SSRI.
        </p>
        <p>
         We are cautious in adding an SSRI to
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         as there is the possibility that clomipramine can raise the blood levels and adverse effects of most SSRIs. These adverse effects include serotonin syndrome, characterized by mental status changes (eg, agitation, hallucinations, delirium, and coma), autonomic instability (eg, tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (eg, nausea, vomiting, diarrhea). This is particularly true with the combination of clomipramine and the SSRIs,
         <a class="drug drug_pediatric" data-topicid="13315" href="/z/d/drug information/13315.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_pediatric" data-topicid="13025" href="/z/d/drug information/13025.html" rel="external">
          fluvoxamine
         </a>
         , or
         <a class="drug drug_pediatric" data-topicid="12681" href="/z/d/drug information/12681.html" rel="external">
          paroxetine
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/301.html" rel="external">
          "Serotonin syndrome (serotonin toxicity)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Drug-drug interactions'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14675.html" rel="external">
          "Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects", section on 'Serotonin syndrome'
         </a>
         .)
        </p>
        <p>
         SSRIs can also raise the blood levels and hence the adverse effects of
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         (eg, QTc prolongation and seizures).
        </p>
        <p>
         Uncontrolled studies of 13 youth with OCD have suggested that therapeutic effects of
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         may be improved and adverse effects reduced by using low doses of each drug [
         <a href="#rid56">
          56,57
         </a>
         ]. In particular, doses of clomipramine should not exceed 75 mg/d unless the blood clomipramine level is monitored. ECG monitoring of the QTc interval is also recommended [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1186172576">
         <span class="h1">
          TREATMENTS WITH LIMITED SUPPORT
         </span>
        </p>
        <p class="headingAnchor" id="H1906026015">
         <span class="h2">
          Glutamate modulators
         </span>
         <span class="headingEndMark">
          —
         </span>
         Converging lines of evidence suggest that glutamate has an important role in the neurobiology of obsessive-compulsive disorder (OCD) [
         <a href="#rid59">
          59
         </a>
         ]. Several glutamate-modulating agents have been used and/or tested in the treatment of OCD; however, limited data support their use. We do not use these medications as treatment for pediatric OCD unless symptoms persist despite the above measures. Their use is in adult OCD is reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14629.html" rel="external">
          "Management of obsessive-compulsive disorder in adults"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Riluzole
         </strong>
         – Despite promising preliminary results [
         <a href="#rid60">
          60
         </a>
         ], in a randomized trial, 51 subjects were assigned to 12 weeks of treatment with
         <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">
          riluzole
         </a>
         versus placebo. At treatment end, similar improvements were reported between treatment and placebo groups [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          N-
         </strong>
         <strong>
          acetylcysteine
         </strong>
         <strong>
          (NAC)
         </strong>
         – Initial reports from a 12-week, double-blind, placebo-controlled randomized trial [
         <a href="#rid62">
          62
         </a>
         ] and from several case studies [
         <a href="#rid63">
          63-65
         </a>
         ] have noted that augmentation of serotonin reuptake inhibitor (SRI) treatment with NAC, an antioxidant molecule that modulates glutamate transmission in the brain, successfully decreased OCD symptom severity in participants with treatment refractory OCD. However, the results from a 16-week, double-blind, placebo-controlled randomized trial [
         <a href="#rid66">
          66
         </a>
         ] and an additional case study [
         <a href="#rid67">
          67
         </a>
         ] were mixed. Evidence to support the use of NAC to augment more traditional OCD therapies remains limited at this time. Further studies are warranted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          D-
         </strong>
         <strong>
          cycloserine
         </strong>
         <strong>
         </strong>
         – In a trial, 27 youth with OCD compared were randomly assigned to 50 mg of d-cycloserine or placebo given immediately after each of 10 cognitive-behavioral therapy sessions. Both groups improved and maintained their gains at one-year follow-up, but no significant advantage was seen between groups at any time point [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Memantine
         </strong>
         – A single case report describing OCD symptom remission supports use of
         <a class="drug drug_general" data-topicid="10131" href="/z/d/drug information/10131.html" rel="external">
          memantine
         </a>
         [
         <a href="#rid69">
          69
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1228808687">
         <span class="h2">
          Neuromodulation therapies/surgical lesioning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Use of neurostimulation with transcranial magnetic stimulation
         <strong>
         </strong>
         (TMS) or deep brain stimulation (DBS), or other surgical lesioning is not recommended for pediatric OCD cases.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          TMS
         </strong>
         – TMS has been found to be well-tolerated as a treatment for a number of other pediatric disorders [
         <a href="#rid70">
          70,71
         </a>
         ]. However, there are currently no studies which have examined the use of repetitive TMS in pediatric OCD and its use is currently not recommended for pediatric OCD cases.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neurosurgery
         </strong>
         – Neurosurgical techniques for OCD, such as DBS or surgical lesioning, are not indicated for children and adolescents. A substantial proportion of pediatric OCD cases remit over the long-term and using invasive neurosurgical techniques of unknown efficacy are not appropriate for pediatric OCD.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1295871982">
         <span class="h2">
          Others
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following agents have minimal support as monotherapy or augmenting agents in the treatment of pediatric OCD. We do not typically use these agents for treatment of pediatric OCD.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="12559" href="/z/d/drug information/12559.html" rel="external">
          Lithium
         </a>
         augmentation of selective serotonin reuptake inhibitors (SSRIs) and
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         [
         <a href="#rid72">
          72,73
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_pediatric" data-topicid="13102" href="/z/d/drug information/13102.html" rel="external">
          Buspirone
         </a>
         augmentation of SSRIs [
         <a href="#rid74">
          74
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Thyroid-hormone augmentation of
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         [
         <a href="#rid73">
          73
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H66007360">
         <span class="h1">
          TREATMENT OF ASSOCIATED SYNDROMES
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tic-related obsessive-compulsive disorder (OCD)
         </strong>
         – For individuals with a comorbid tic disorder or tic-related OCD, we prefer initial treatment with cognitive-behavioral therapy (CBT) with or without pharmacotherapy with a selective serotonin reuptake inhibitor (SSRI) [
         <a href="#rid40">
          40
         </a>
         ]. The presence of a comorbid tic disorder does not appear to impact response to CBT, but may predict a poorer response to pharmacotherapy in the acute treatment of pediatric OCD [
         <a href="#rid75">
          75,76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Individuals who do not respond to CBT may benefit from supplementing CBT with pharmacotherapy with an SSRI [
         <a href="#rid40">
          40,77
         </a>
         ]. Individuals who do not respond to an SSRI, or have severe tics, may require additional supplementation with an antipsychotic medication (eg,
         <a class="drug drug_pediatric" data-topicid="12770" href="/z/d/drug information/12770.html" rel="external">
          risperidone
         </a>
         or
         <a class="drug drug_pediatric" data-topicid="13180" href="/z/d/drug information/13180.html" rel="external">
          aripiprazole
         </a>
         ) [
         <a href="#rid52">
          52
         </a>
         ]. However, due to serious metabolic side effects, symptoms and side effects should be monitored carefully, and all indicated laboratory tests should be completed at baseline, three-month, and one-year follow-up.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pediatric autoimmune neuropsychiatric disorders (PANDAS/PANS)
         </strong>
         – Our treatment of OCD symptoms and behaviors in children with a possible diagnosis of pediatric autoimmune neuropsychiatric disorder associated with group A streptococci [PANDAS]) or pediatric acute-onset neuropsychiatric syndrome (PANS) is based on the recommendations described here for OCD, whether the patient has evidence of recent group A streptococci infection [
         <a href="#rid12">
          12,40,78,79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do not delay treatment of psychiatric symptoms pending confirmation or treatment of PANDAS. Treatment of PANDAS is described in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/6031.html" rel="external">
          "PANDAS: Pediatric autoimmune neuropsychiatric disorder associated with group A streptococci", section on 'Management'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H612093052">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115511.html" rel="external">
          "Society guideline links: Obsessive-compulsive disorder and related disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19048561">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Obsessive-compulsive disorder (OCD)
         </strong>
         – OCD typically starts in childhood or adolescence. It is characterized by recurrent intrusive thoughts, images, or urges that cause anxiety or distress (obsessions), and by repetitive mental or behavioral acts (compulsions) that the individual feels driven to perform (often in response to obsessions). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial treatment
         </strong>
         – Our preference for initial treatment is based on results of clinical trials. We consider symptom severity, past treatment history, and the presence of active comorbid disorders. We prioritize patient/caregiver preference and typically initiate treatment with the patient-preferred option  (
         <a class="graphic graphic_algorithm graphicRef143692" href="/z/d/graphic/143692.html" rel="external">
          algorithm 1
         </a>
         ). (See
         <a class="local">
          'Initial treatment'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Mild to moderate symptoms
         </strong>
         – For youth with mild to moderate symptoms, who do not have an active co-occurring disorder we suggest cognitive-behavioral therapy with exposure and response prevention (CBT-ERP), rather than medication management, as the first treatment choice (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). (See
         <a class="local">
          'Mild or moderate symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Severe symptoms or active comorbid disorder
         </strong>
         – For youth with severe symptoms, or in those with an active comorbid disorder (eg, depression, anxiety) we suggest treatment with combined modality, including cognitive-behavioral therapy (CBT) and pharmacotherapy, rather than either alone (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Initial
         </strong>
         <strong>
          pharmacologic management
         </strong>
         – For youth with OCD who will be treated with pharmacologic management (either with or without psychotherapy) we suggest treatment with a selective serotonin reuptake inhibitor (SSRI) rather than other categories of antidepressants or
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Suicidality
         </strong>
         – While there is controversy about the relationship between SSRI use and suicidality in children, we monitor children or adolescents who are treated with SSRIs weekly during the first month, and at least monthly thereafter. (See
         <a class="local">
          'Suicidality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subsequent treatment
         </strong>
         – For individuals with inadequate response to initial treatment we confirm adherence to treatment recommendations (ie, taking medication as recommended, engaged in CBT), reconfirm the diagnosis, and assess for the presence of an undiagnosed comorbid disorder. (See
         <a class="local">
          'Inadequate response'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Longer term CBT
         </strong>
         - For patients with pediatric OCD who initially have a partial response, or fail to respond to CBT treatment, our preference is additional CBT treatment to reduce symptoms. (See
         <a class="local">
          'Longer term cognitive-behavioral therapy with exposure-response prevention'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Subsequent pharmacologic options
         </strong>
         – Subsequent pharmacologic management of youth with inadequate response to management to this point includes the following in sequential order:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Treatment with SSRI – Our preference is to give two SSRI trials prior to other pharmacologic options. For those that have not been on an SSRI, we begin one. For those already on an SSRI, we change to another SSRI. (See
         <a class="local">
          'SSRI trials'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Change to
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          clomipramine
         </a>
         . (See
         <a class="local">
          'Change to clomipramine'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         Augment with a second-generation antipsychotic. (See
         <a class="local">
          'Augment with a second-generation antipsychotic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <a class="drug drug_pediatric" data-topicid="13050" href="/z/d/drug information/13050.html" rel="external">
          Clomipramine
         </a>
         plus SSRI. (See
         <a class="local">
          'Clomipramine plus SSRI'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of associated syndromes
         </strong>
         (see
         <a class="local">
          'Treatment of associated syndromes'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tic-related OCD
         </strong>
         – For individuals with a comorbid tic disorder or tic-related OCD, we prefer initial treatment with CBT with or without pharmacotherapy with an SSRI. The presence of a comorbid tic disorder may predict a poorer response to pharmacotherapy in the acute treatment of pediatric OCD.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Pediatric autoimmune neuropsychiatric disorder (PANDAS)
         </strong>
         – Our preference is to treat youth with OCD symptoms and behaviors possibly due to a diagnosis of pediatric autoimmune neuropsychiatric disorder associated with group A streptococci (PANDAS) based on the recommendations above. We do not delay treatment of psychiatric symptoms pending confirmation of PANDAS.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Franklin ME, Goss A, March JS. Cognitive behavioral therapy in obsessive-compulsive disorder: state of the art. In: Obsessive Compulsive Disorder: Current Science and Clinical Practice, Zohar J (Ed), Wiley-Blackwell, Hoboken, NJ 2012. p.58.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Franklin ME, Kozak MJ, Cashman LA, et al. Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial. J Am Acad Child Adolesc Psychiatry 1998; 37:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett P, Healy-Farrell L, March JS. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Himle JA, Rassi S, Haghighatgou H, et al. Group behavioral therapy of obsessive-compulsive disorder: seven vs. twelve-week outcomes. Depress Anxiety 2001; 13:161.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aspvall K, Andersson E, Melin K, et al. Effect of an Internet-Delivered Stepped-Care Program vs In-Person Cognitive Behavioral Therapy on Obsessive-Compulsive Disorder Symptoms in Children and Adolescents: A Randomized Clinical Trial. JAMA 2021; 325:1863.
          </a>
         </li>
         <li class="breakAll">
          Bieling PJ, Blasioli E, Friedman-Wheeler DG. Cognitive case formulation. In: Handbook of Cognitive Behavioral Therapy: Overview and Approaches, Wenzel A (Ed), American Psychological Association, 2021. p.131.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA 2004; 292:1969.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skarphedinsson G, Hanssen-Bauer K, Kornør H, et al. Standard individual cognitive behaviour therapy for paediatric obsessive-compulsive disorder: a systematic review of effect estimates across comparisons. Nord J Psychiatry 2015; 69:81.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Uhre CF, Uhre VF, Lønfeldt NN, et al. Systematic Review and Meta-Analysis: Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in Children and Adolescents. J Am Acad Child Adolesc Psychiatry 2020; 59:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bolton D, Williams T, Perrin S, et al. Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder. J Child Psychol Psychiatry 2011; 52:1269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGuire JF, Piacentini J, Lewin AB, et al. A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION. Depress Anxiety 2015; 32:580.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998; 280:1752.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller DA, Wagner KD, Emslie G, et al. Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2004; 43:1387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller DA, Biederman J, Stewart SE, et al. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am J Psychiatry 2003; 160:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Geller DA, Hoog SL, Heiligenstein JH, et al. Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebowitz MR, Turner SM, Piacentini J, et al. Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002; 41:1431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 2001; 40:222.
          </a>
         </li>
         <li class="breakAll">
          Sakolsky D, Birmaher B. Selective serotonin reuptake inhibitors (SSRIs). In: Pharmacotherapy of Child and Adolescent Psychiatric Disorders, Rosenberg DR, Gershon S (Eds), Wiley-Blackwell, Hoboken, NJ 2012. p.155.
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeVeaugh-Geiss J, Moroz G, Biederman J, et al. Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial. J Am Acad Child Adolesc Psychiatry 1992; 31:45.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Freeman CP, Trimble MR, Deakin JF, et al. Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. J Clin Psychiatry 1994; 55:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koran LM, McElroy SL, Davidson JR, et al. Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 1996; 16:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mundo E, Maina G, Uslenghi C. Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2000; 15:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results. Arch Gen Psychiatry 1990; 47:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           López-Ibor JJ Jr, Saiz J, Cottraux J, et al. Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder. Eur Neuropsychopharmacol 1996; 6:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996; 169:468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bisserbe J, Lane R, Flament M, Franco-Belgian OCD Study Group. A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder. Eur Psychiatry 1997; 12:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tao Y, Li H, Li L, et al. Comparing the efficacy of pharmacological and psychological treatment, alone and in combination, in children and adolescents with obsessive-compulsive disorder: A network meta-analysis. J Psychiatr Res 2022; 148:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bridge JA, Iyengar S, Salary CB, et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials. JAMA 2007; 297:1683.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin A, Young C, Leckman JF, et al. Age effects on antidepressant-induced manic conversion. Arch Pediatr Adolesc Med 2004; 158:773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloch MH, Storch EA. Assessment and management of treatment-refractory obsessive-compulsive disorder in children. J Am Acad Child Adolesc Psychiatry 2015; 54:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wagner KD, Cook EH, Chung H, Messig M. Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2003; 13 Suppl 1:S53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40:1175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dwyer JB, Bloch MH. Antidepressants for Pediatric Patients. Curr Psychiatr 2019; 18:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cheung AH, Emslie GJ, Mayes TL. The use of antidepressants to treat depression in children and adolescents. CMAJ 2006; 174:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emslie G, Kratochvil C, Vitiello B, et al. Treatment for Adolescents with Depression Study (TADS): safety results. J Am Acad Child Adolesc Psychiatry 2006; 45:1440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol 2006; 16:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mills JA, Strawn JR. Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis. J Am Acad Child Adolesc Psychiatry 2020; 59:1240.
          </a>
         </li>
         <li class="breakAll">
          Ryan CA, Trieu ML. Pediatric Psychopharmacology. In: Psychologists' Desk Reference, 3rd ed, Koocher GP, Norcross JC, Greene BA (Eds), Oxford University Press, 2013. p.455.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Wyatt D, Spencer TJ. Disentangling disinhibition. J Am Acad Child Adolesc Psychiatry 1998; 37:1225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           March JS, Franklin ME, Leonard H, et al. Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder. Biol Psychiatry 2007; 61:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skarphedinsson G, Weidle B, Thomsen PH, et al. Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial. Eur Child Adolesc Psychiatry 2015; 24:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotapati VP, Khan AM, Dar S, et al. The Effectiveness of Selective Serotonin Reuptake Inhibitors for Treatment of Obsessive-Compulsive Disorder in Adolescents and Children: A Systematic Review and Meta-Analysis. Front Psychiatry 2019; 10:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storch EA, Bussing R, Small BJ, et al. Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder. Behav Res Ther 2013; 51:823.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Neill J, Feusner JD. Cognitive-behavioral therapy for obsessive-compulsive disorder: access to treatment, prediction of long-term outcome with neuroimaging. Psychol Res Behav Manag 2015; 8:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barrett P, Farrell L, Dadds M, Boulter N. Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: long-term follow-up and predictors of outcome. J Am Acad Child Adolesc Psychiatry 2005; 44:1005.
          </a>
         </li>
         <li class="breakAll">
          Ivarsson T, Skarphedinsson G, Weidle B. Medication management of childhood OCD. In: The Clinician's Guide to Cognitive-Behavioral Therapy for Childhood Obsessive-Compulsive Disorder, Storch EA, McGuire JF, McKay D (Eds), Elsevier Academic Press, 2018. p.155.
         </li>
         <li class="breakAll">
          Heleniak CM, Kaur T, Ghslib KD, Rynn MA. Tricyclic antidepressants and monoamine oxidase inhibitors for the treatment of child and adolescent psychiatric disorders. In: Obsessive Compulsive Disorder: Current Science and Clinical Practice, Zohar J (Ed), Wiley-Blackwell, Hoboken, NJ 2012. p.105.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandel P, Regina W, Reix I, et al. [Grapefruit juice as a contraindication? An approach in psychiatry]. Encephale 1999; 25:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Meca J, Rosa-Alcázar AI, Iniesta-Sepúlveda M, Rosa-Alcázar A. Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: a meta-analysis. J Anxiety Disord 2014; 28:31.
          </a>
         </li>
         <li class="breakAll">
          Pharmacotherapy of Child and Adolescent Psychiatric Disorders, 3rd ed., Rosenberg DR, Gershon S (Eds), Wiley-Blackwell, United Kingdom 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35:205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Pfanner C, Brovedani P. Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study. J Psychiatr Res 2013; 47:1007.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Millepiedi S, Perugi G, et al. Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study. CNS Drugs 2009; 23:241.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masi G, Pfanner C, Millepiedi S, Berloffa S. Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder. J Clin Psychopharmacol 2010; 30:688.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR. Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharmacol 1999; 9:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simeon JG, Thatte S, Wiggins D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol Bull 1990; 26:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Figueroa Y, Rosenberg DR, Birmaher B, Keshavan MS. Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents. J Child Adolesc Psychopharmacol 1998; 8:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Andrade C. Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks. J Clin Psychiatry 2013; 74:e1128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Macmaster FP, Rosenberg DR. Glutamate and the Treatment of Obsessive-Compulsive Disorder. Psychopharm Rev 2010; 45:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant P, Lougee L, Hirschtritt M, Swedo SE. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J Child Adolesc Psychopharmacol 2007; 17:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grant PJ, Joseph LA, Farmer CA, et al. 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder. Neuropsychopharmacology 2014; 39:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Afshar H, Roohafza H, Mohammad-Beigi H, et al. N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychopharmacol 2012; 32:797.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafleur DL, Pittenger C, Kelmendi B, et al. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology (Berl) 2006; 184:254.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazici KU, Percinel I. The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation. J Child Adolesc Psychopharmacol 2014; 24:525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yazici KU, Percinel I. N-Acetylcysteine Augmentation in Children and Adolescents Diagnosed With Treatment-Resistant Obsessive-Compulsive Disorder: Case Series. J Clin Psychopharmacol 2015; 35:486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sarris J, Oliver G, Camfield DA, et al. N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study. CNS Drugs 2015; 29:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van Ameringen M, Patterson B, Simpson W, et al. N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: a case series. J Obsessive Compuls Relat Disord 2013; 2:48.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mataix-Cols D, Turner C, Monzani B, et al. Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial. Br J Psychiatry 2014; 204:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hezel DM, Beattie K, Stewart SE. Memantine as an augmenting agent for severe pediatric OCD. Am J Psychiatry 2009; 166:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen CH, Kluger BM, Buard I. Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature. Pediatr Neurol 2017; 68:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zewdie E, Ciechanski P, Kuo HC, et al. Safety and tolerability of transcranial magnetic and direct current stimulation in children: Prospective single center evidence from 3.5 million stimulations. Brain Stimul 2020; 13:565.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDougle CJ, Price LH, Goodman WK, et al. A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy. J Clin Psychopharmacol 1991; 11:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pigott TA, Pato MT, L'Heureux F, et al. A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grady TA, Pigott TA, L'Heureux F, et al. Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder. Am J Psychiatry 1993; 150:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Storch EA, Merlo LJ, Larson MJ, et al. Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2008; 47:583.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia AM, Sapyta JJ, Moore PS, et al. Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I). J Am Acad Child Adolesc Psychiatry 2010; 49:1024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skarphedinsson G, Compton S, Thomsen PH, et al. Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy. J Child Adolesc Psychopharmacol 2015; 25:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thienemann M, Murphy T, Leckman J, et al. Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I-Psychiatric and Behavioral Interventions. J Child Adolesc Psychopharmacol 2017; 27:566.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swedo SE, Leonard HL, Rapoport JL. The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction. Pediatrics 2004; 113:907.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 90748 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Franklin ME, Goss A, March JS. Cognitive behavioral therapy in obsessive-compulsive disorder: state of the art. In: Obsessive Compulsive Disorder: Current Science and Clinical Practice, Zohar J (Ed), Wiley-Blackwell, Hoboken, NJ 2012. p.58.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9549962" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Cognitive-behavioral treatment of pediatric obsessive-compulsive disorder: an open clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14691360" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: a controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11413562" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Group behavioral therapy of obsessive-compulsive disorder: seven vs. twelve-week outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33974020" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Effect of an Internet-Delivered Stepped-Care Program vs In-Person Cognitive Behavioral Therapy on Obsessive-Compulsive Disorder Symptoms in Children and Adolescents: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33974020" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Effect of an Internet-Delivered Stepped-Care Program vs In-Person Cognitive Behavioral Therapy on Obsessive-Compulsive Disorder Symptoms in Children and Adolescents: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15507582" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25142430" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Standard individual cognitive behaviour therapy for paediatric obsessive-compulsive disorder: a systematic review of effect estimates across comparisons.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31589909" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Systematic Review and Meta-Analysis: Cognitive-Behavioral Therapy for Obsessive-Compulsive Disorder in Children and Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21644984" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Randomized controlled trial of full and brief cognitive-behaviour therapy and wait-list for paediatric obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26130211" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : A META-ANALYSIS OF COGNITIVE BEHAVIOR THERAPY AND MEDICATION FOR CHILD OBSESSIVE-COMPULSIVE DISORDER: MODERATORS OF TREATMENT EFFICACY, RESPONSE, AND REMISSION.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9842950" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15502598" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14594734" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11437015" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12447029" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Fluoxetine in children and adolescents with OCD: a placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11211371" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11211371" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1537780" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder--a multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8071291" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8690827" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10759337" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Multicentre, double-blind, comparison of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2222131" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Behavioral and biological results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8791036" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Double-blind comparison of fluoxetine versus clomipramine in the treatment of obsessive compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8894198" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19698511" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A double-blind comparison of sertraline and clomipramine in outpatients with obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35121274" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Comparing the efficacy of pharmacological and psychological treatment, alone and in combination, in children and adolescents with obsessive-compulsive disorder: A network meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17440145" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289250" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Age effects on antidepressant-induced manic conversion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25791142" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Assessment and management of treatment-refractory obsessive-compulsive disorder in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12880500" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Remission status after long-term sertraline treatment of pediatric obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11589530" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31511767" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Antidepressants for Pediatric Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16415467" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The use of antidepressants to treat depression in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17135989" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treatment for Adolescents with Depression Study (TADS): safety results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16553536" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31682918" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31682918" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9808935" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Disentangling disinhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17241830" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25239489" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Continued cognitive-behavior therapy versus sertraline for children and adolescents with obsessive-compulsive disorder that were non-responders to cognitive-behavior therapy: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31447707" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The Effectiveness of Selective Serotonin Reuptake Inhibitors for Treatment of Obsessive-Compulsive Disorder in Adolescents and Children: A Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24184429" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Randomized, placebo-controlled trial of cognitive-behavioral therapy alone or combined with sertraline in the treatment of pediatric obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26229514" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cognitive-behavioral therapy for obsessive-compulsive disorder: access to treatment, prediction of long-term outcome with neuroimaging.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175105" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: long-term follow-up and predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175105" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: long-term follow-up and predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16175105" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Cognitive-behavioral family treatment of childhood obsessive-compulsive disorder: long-term follow-up and predictors of outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10205736" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : [Grapefruit juice as a contraindication? An approach in psychiatry].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24334214" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24334214" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Differential efficacy of cognitive-behavioral therapy and pharmacological treatments for pediatric obsessive-compulsive disorder: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12518268" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23664673" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antipsychotic augmentation of selective serotonin reuptake inhibitors in resistant tic-related obsessive-compulsive disorder in children and adolescents: a naturalistic comparative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19320532" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Pharmacotherapy in paediatric obsessive-compulsive disorder: a naturalistic, retrospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21105283" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10461822" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2274627" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9639080" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Combination treatment with clomipramine and selective serotonin reuptake inhibitors for obsessive-compulsive disorder in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24434100" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Augmenting selective serotonin reuptake inhibitors with clomipramine in obsessive-compulsive disorder: benefits and risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24634707" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Glutamate and the Treatment of Obsessive-Compulsive Disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18315448" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24356715" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : 12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23131885" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : N-acetylcysteine add-on treatment in refractory obsessive-compulsive disorder: a randomized, double-blind, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16374600" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25264963" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : The role of glutamatergic dysfunction in treatment-resistant obsessive-compulsive disorder: treatment of an adolescent case with N-acetylcysteine augmentation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26066338" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : N-Acetylcysteine Augmentation in Children and Adolescents Diagnosed With Treatment-Resistant Obsessive-Compulsive Disorder: Case Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26374743" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : N-Acetyl Cysteine (NAC) in the Treatment of Obsessive-Compulsive Disorder: A 16-Week, Double-Blind, Randomised, Placebo-Controlled Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : N-acetylcysteine augmentation in treatment resistant obsessive compulsive disorder: a case series
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24262813" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Cognitive-behavioural therapy with post-session D-cycloserine augmentation for paediatric obsessive-compulsive disorder: pilot randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19188297" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Memantine as an augmenting agent for severe pediatric OCD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28216033" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Safety of Transcranial Magnetic Stimulation in Children: A Systematic Review of the Literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32289678" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Safety and tolerability of transcranial magnetic and direct current stimulation in children: Prospective single center evidence from 3.5 million stimulations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1820757" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : A controlled trial of lithium augmentation in fluvoxamine-refractory obsessive-compulsive disorder: lack of efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1918422" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8480832" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Double-blind study of adjuvant buspirone for fluoxetine-treated patients with obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18356759" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Impact of comorbidity on cognitive-behavioral therapy response in pediatric obsessive-compulsive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20855047" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Predictors and moderators of treatment outcome in the Pediatric Obsessive Compulsive Treatment Study (POTS I).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26091197" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Tics Moderate Sertraline, but Not Cognitive-Behavior Therapy Response in Pediatric Obsessive-Compulsive Disorder Patients Who Do Not Respond to Cognitive-Behavior Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28722481" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Clinical Management of Pediatric Acute-Onset Neuropsychiatric Syndrome: Part I-Psychiatric and Behavioral Interventions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15060242" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection (PANDAS) subgroup: separating fact from fiction.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
